Skip to main content
SpringerLink
Log in

The quantification of circular RNA 0007841 during induction therapy helps estimate the response and survival benefits to bortezomib-based regimen in multiple myeloma

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Objective

Circular RNA_0007841 (Circ_0007841) facilitates multiple myeloma (MM) progression and resistance of the bortezomib by experimental studies, while its clinical implication in MM patients is still unclear. This study intended to evaluate the longitudinal change and prognostic role of circ_0007841 expression in MM patients receiving bortezomib-based induction therapy.

Methods

In this prospective study, bone marrow plasma cell (BMPC) samples were gained from 97 MM patients at diagnosis and after bortezomib-based induction therapy, and from 30 healthy controls (HCs) proposing BM donation. Then, circ_0007841 expression in BMPC samples was measured by reverse transcription-quantitative polymerase chain reaction. Additionally, MM patients were followed up for a median of 29.4 months.

Results

Circ_0007841 expression was increased in MM patients compared to HCs (P < 0.001), but it was decreased after bortezomib-based induction therapy in MM patients (P < 0.001). Moreover, circ_0007841 expression at diagnosis was associated with the presence of t (4; 14) (P = 0.034), while its expression after bortezomib-based induction therapy was linked with higher revised international staging system stage (P = 0.025) in MM patients. Interestingly, circ_0007841 expression after bortezomib-based induction therapy was lower in MM patients who achieved complete remissions (P = 0.001) and overall responses (P = 0.002) compared to those who did not. Prognostically, circ_0007841 expression after bortezomib-based induction therapy (over the median vs. below the median) independently predicted shorter progression-free survival (hazard ratio (HR): 2.497, P = 0.002) and overall survival (HR: 3.107, P = 0.008) in MM patients.

Conclusion

Circ_0007841 quantification during induction therapy may reflect the response and survival benefits to bortezomib-based regimen in MM patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data Availability

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

References

  1. van de Donk N, Pawlyn C, Yong KL et al (2021) Multiple myeloma. Lancet 397(10272):410–427

    Article  PubMed  Google Scholar 

  2. Cowan AJ, Green DJ, Kwok M et al (2022) Diagnosis and Management of Multiple Myeloma: A Review. JAMA 327(5):464–477

    Article  CAS  PubMed  Google Scholar 

  3. Wallington-Beddoe CT, Mynott RL (2021) Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol 14(1):151

    Article  PubMed  PubMed Central  Google Scholar 

  4. Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209–249

    Article  PubMed  Google Scholar 

  5. Zhao Y, Niu D, Ye E et al (2022) Secular Trends in the Burden of Multiple Myeloma From 1990 to 2019 and Its Projection Until 2044 in China. Front Public Health 10:938770

    Article  PubMed  PubMed Central  Google Scholar 

  6. Huang J, Chan SC, Lok V et al (2022) The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol 9(9):e670–e677

    Article  Google Scholar 

  7. Branagan A, Lei M, Lou U, Raje N (2020) Current Treatment Strategies for Multiple Myeloma. JCO Oncol Pract 16(1):5–14

    Article  PubMed  Google Scholar 

  8. Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95(5):548–567

    Article  CAS  PubMed  Google Scholar 

  9. Ding K, Jiang W, Jia H, Lei M (2022) Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib. Biomolecules 12(11)

  10. Kozalak G, Butun I, Toyran E, Kosar A (2023) Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies. Pharmaceuticals (Basel) 16(1)

  11. Palumbo A, Chanan-Khan A, Weisel K et al (2016) Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 375(8):754–766

    Article  CAS  PubMed  Google Scholar 

  12. Xia J, He Y, Meng B et al (2020) NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma. Mol Oncol 14(4):763–778

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Cao YZ, Sun JY, Chen YX et al (2021) The roles of circRNAs in cancers: Perspectives from molecular functions. Gene 767:145182

    Article  CAS  PubMed  Google Scholar 

  14. Chen L, Shan G (2021) CircRNA in cancer: Fundamental mechanism and clinical potential. Cancer Lett 505:49–57

    Article  CAS  PubMed  Google Scholar 

  15. Zhao X, Cai Y, Xu J (2019) Circular RNAs: Biogenesis, Mechanism, and Function in Human Cancers. Int J Mol Sci 20(16)

  16. Tang X, Ren H, Guo M et al (2021) Review on circular RNAs and new insights into their roles in cancer. Comput Struct Biotechnol J 19:910–928

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wang Y, Lin Q, Song C et al (2020) Circ_0007841 promotes the progression of multiple myeloma through targeting miR-338-3p/BRD4 signaling cascade. Cancer Cell Int 20:383

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wang Y, Lin Q, Song C et al (2020) Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis. Cell Cycle 19(23):3289–3302

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ludwig H, Miguel JS, Dimopoulos MA et al (2014) International Myeloma Working Group recommendations for global myeloma care. Leukemia 28(5):981–992

    Article  CAS  PubMed  Google Scholar 

  20. Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420

    Article  PubMed  Google Scholar 

  21. Palumbo A, Avet-Loiseau H, Oliva S et al (2015) Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 33(26):2863–2869

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Gao M, Li C, Xiao H et al (2019) hsa_circ_0007841: A Novel Potential Biomarker and Drug Resistance for Multiple Myeloma. Front Oncol 9:1261

    Article  PubMed  PubMed Central  Google Scholar 

  23. Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346

    Article  PubMed  Google Scholar 

  24. Huang K, Liu D, Su C (2021) Circ_0007841 accelerates ovarian cancer development through facilitating MEX3C expression by restraining miR-151-3p activity. Aging (Albany NY) 13(8):12058–12066

    Article  CAS  PubMed  Google Scholar 

  25. Long F, Li Z, Wei Z, Xie Y (2022) Circular RNA circ_0007841 participates in progression of nonsmall cell lung cancer via miR-199a-5p/SphK2 axis. Anticancer Drugs 33(10):1035–1046

    Article  CAS  PubMed  Google Scholar 

  26. Song Y, Hu N, Song X, Yang J (2020) Hsa_Circ_0007841 Enhances Multiple Myeloma Chemotherapy Resistance Through Upregulating ABCG2. Technol Cancer Res Treat 19:1533033820928371

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Viol Ferreira Lopes MA, Higashi F, Crusoe EQ et al (2022) Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life. Hematol Transfus Cell Ther

  28. Rajkumar SV (2016) Myeloma today: Disease definitions and treatment advances. Am J Hematol 91(1):90–100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Bonello F, Cani L, D’Agostino M (2022) Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting. Front Oncol 12:830922

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zhong L, Hao P, Zhang Q et al (2022) Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM). Elife 11

Download references

Acknowledgements

None.

Funding

None.

Author information

Author notes

  1. Yigang Guo and Xuelian Feng contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology, Taihe Hospital, Hubei University of Medicine, Hubei, China

    Yigang Guo, Jinyun Xu, Ping Hu & Rongyao Zhang

  2. Children’s Medical Center, Taihe Hospital, Hubei University of Medicine, Hubei, China

    Xuelian Feng, Zhen Wang, Ruibo Zhang & Kun Zheng

Authors
  1. Yigang Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuelian Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ruibo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kun Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jinyun Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ping Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rongyao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xuelian Feng.

Ethics declarations

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (TIF 504 KB)

Supplementary file2 (DOCX 16 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, Y., Feng, X., Wang, Z. et al. The quantification of circular RNA 0007841 during induction therapy helps estimate the response and survival benefits to bortezomib-based regimen in multiple myeloma. Ir J Med Sci 193, 17–25 (2024). https://doi.org/10.1007/s11845-023-03410-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-023-03410-w

Keywords

Search

Navigation